Clinical Trials Logo

Clinical Trial Summary

Phosphorus-based food additives are commonly used by food manufacturers for many applications, such as enhancing flavor, in ready-to-eat foods and beverages. While these additives can significantly increase an individual's daily phosphorus intake, little is known about the effect of dietary phosphorus on kidney health. In this study, the investigators will first lower baseline phosphorus intake to about 1000mg/d by educating participants to avoid foods with phosphorus additives. Then, participants will be randomized to a higher phosphorus period (~2gm/d) and a lower phosphorus period (~1gm/d) by providing unaltered, commercially-available food/beverage products with and without phosphorus additives.

The investigators hypothesize that participants will have higher urine albumin excretion and fibroblast growth factor-23 (FGF-23) during the higher phosphorus period compared to the lower phosphorus period.


Clinical Trial Description

The Study of Dietary Additive Phosphorus on Proteinuria and FGF-23 (SODA-POP) was a single-center, randomized, double-blind, two-period cross-over study that examined the effect of higher vs. lower phosphorus intake for 3 week periods, achieved by addition of commercially available diet beverages and breakfast bars to diet on albuminuria and fibroblast growth factor 23, in adults with presumed early chronic kidney disease (estimated glomerular filtration rate >= 45 ml/min/1.73m2; and urine albumin/creatinine ratio >=17 mg/g for men or >=25 mg/g for women). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02020785
Study type Interventional
Source Geisinger Clinic
Contact
Status Completed
Phase N/A
Start date January 2014
Completion date September 2015

See also
  Status Clinical Trial Phase
Completed NCT00095290 - Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria Phase 4
Completed NCT02144740 - Effect of NWT-03 on Blood Pressure N/A
Completed NCT01041599 - Correlation of Albuminuria With Arterial Stiffness N/A
Active, not recruiting NCT05321095 - Screening for Albuminuria at the First Line for Early Identification of CKD
Completed NCT02945969 - Sodium Lowering and Urinary Protein Reduction Trial Phase 3
Enrolling by invitation NCT04295889 - Towards HOMe-based Albuminuria Screening: an Implementation Study Testing Two Approaches N/A
Recruiting NCT04272359 - Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus
Completed NCT03889236 - Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy. N/A
Active, not recruiting NCT00625820 - Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria Phase 2
Recruiting NCT04752293 - Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
Completed NCT03118739 - Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria Phase 2
Completed NCT06374043 - Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin. Phase 4
Completed NCT03396328 - Effects of Intensive Low-Salt Diet Education by Mobile Application on Albuminuria N/A
Not yet recruiting NCT06094920 - Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial Phase 4
Recruiting NCT00342927 - Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
Completed NCT02689778 - Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy Phase 3
Completed NCT02497300 - Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease Phase 2
Completed NCT02446548 - Influence of Aliskiren on Albuminuria After Kidney Transplantation N/A
Completed NCT01547897 - NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria Phase 2
Enrolling by invitation NCT01316068 - Effect of Sulodexide on Albuminuria in Chinese Type 2 Diabetic Patients Phase 4